(VIANEWS) – The NASDAQ ended the session with FibroGen (FGEN) rising 10% to $0.89 on Thursday while NASDAQ dropped 0.03% to $15,095.14.
FibroGen’s last close was $0.81, 96.85% under its 52-week high of $25.69.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.
Sales Growth
FibroGen’s sales growth is 5.3% for the present quarter and 16.4% for the next.
Volatility
FibroGen’s last week, last month’s, and last quarter’s current intraday variation average was 7.30%, 3.13%, and 7.57%.
FibroGen’s highest amplitude of average volatility was 7.30% (last week), 7.77% (last month), and 7.57% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be oversold (<=20).
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is 0.29.
More news about FibroGen (FGEN).
